Cancer Council Victoria | Victorian Cancer Trials Link

# A randomised, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumb versus pembrolizumab alone as a first line treatment for locally advanced or metastatic non-small cell lung cancer with PD-L1 â‰¥ 50%

## Clinical summary

For patients to be eligible to participate in this trial the non-small cell carcinoma needs to have PD-L1 expression of â‰¥ 50% and have no EGFR mutation or ALK rearrangement. Eligible patients will either receive oral tablets of Capmatinib to be taken twice per day and intravenous infusion of Pembrolizumab once every 3 weeks, or 3 weekly infusions of Pembroliumab only.

## Conditions

This trial is treating patients with locally advanced or metastatic non-small cell lung cancer

**Trial Acronym**
CINC280

**Trial Identifiers**
NCT04139317

**Cancer**
Non-Small Cell Lung Cancer

**Age:** 18+
**Phase:** II

**For full trial details, visit trials.cancervic.org.au/details/vctl_nct04139317**